MorphoSys Buys Sloning BioTechnology for $26.5M

According to MorphoSys, the deal will allow it to improve the success rate for new antibody drug candidate development to the point where 50 percent of new projects will reach clinical development.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories